Current stockpiles of first- and second-generation smallpox vaccines serve as an important contingency position for emergent circumstances. Newer-generation smallpox vaccines that employ highly attenuated and/or nonreplicative forms of vaccinia or sub-unit vaccine approaches, some with promising preclinical data, may provide significantly safer, effective alternatives over the next 5 years that will enhance biodefense strategies. Viral subunit strategies, in particular, may provide a flexible platform in the future upon which to build capabilities for protection against genetically altered forms of smallpox.
The authors wish to acknowledge Katherine Bollesen and Margo Katz for administrative assistance with the manuscript.Reprint Address
Andrew W Artenstein, Department of Medicine, Director, Center for Biodefense and Emerging Pathogens and Associate Professor of Medicine and Community Health, Alpert Medical School of Brown University and Department of Medicine, Memorial Hospital of RI, 111 Brewster Street, Pawtucket, RI 02860. E-mail: firstname.lastname@example.org .
Expert Rev Vaccines. 2008;7(8):1225-1237. © 2008 Expert Reviews Ltd.
Cite this: Smallpox Vaccines for Biodefense: Need and Feasibility - Medscape - Oct 01, 2008.